Evaluating the therapeutic potential of curcumin and synthetic derivatives : a computational approach to anti-obesity treatments

dc.contributor.authorMoetlediwa, Marakiya T.
dc.contributor.authorJack, Babalwa U.
dc.contributor.authorMazibuko-Mbeje, Sithandiwe E.
dc.contributor.authorPheiffer, Carmen
dc.contributor.authorTitinchi, Salam J.J.
dc.contributor.authorSalifu, Elliasu Y.
dc.contributor.authorRamharack, Pritika
dc.date.accessioned2025-03-13T04:48:05Z
dc.date.available2025-03-13T04:48:05Z
dc.date.issued2024-02-23
dc.descriptionDATA AVAILABILITY STATEMENT : All additional data including raw data will be provided upon request after this paper is published.en_US
dc.description.abstractNatural compounds such as curcumin, a polyphenolic compound derived from the rhizome of turmeric, have gathered remarkable scientific interest due to their diverse metabolic benefits including anti-obesity potential. However, curcumin faces challenges stemming from its unfavorable pharmacokinetic profile. To address this issue, synthetic curcumin derivatives aimed at enhancing the biological efficacy of curcumin have previously been developed. In silico modelling techniques have gained significant recognition in screening synthetic compounds as drug candidates. Therefore, the primary objective of this study was to assess the pharmacokinetic and pharmacodynamic characteristics of three synthetic derivatives of curcumin. This evaluation was conducted in comparison to curcumin, with a specific emphasis on examining their impact on adipogenesis, inflammation, and lipid metabolism as potential therapeutic targets of obesity mechanisms. In this study, predictive toxicity screening confirmed the safety of curcumin, with the curcumin derivatives demonstrating a safe profile based on their LD50 values. The synthetic curcumin derivative 1A8 exhibited inactivity across all selected toxicity endpoints. Furthermore, these compounds were deemed viable candidate drugs as they adhered to Lipinski’s rules and exhibited favorable metabolic profiles. Molecular docking studies revealed that both curcumin and its synthetic derivatives exhibited favorable binding scores, whilst molecular dynamic simulations showed stable binding with peroxisome proliferator-activated receptor gamma (PPARγ), csyclooxygenase-2 (COX2), and fatty acid synthase (FAS) proteins. The binding free energy calculations indicated that curcumin displayed potential as a strong regulator of PPARγ (−60.2 ± 0.4 kcal/mol) and FAS (−37.9 ± 0.3 kcal/mol), whereas 1A8 demonstrated robust binding affinity with COX2 (−64.9 ± 0.2 kcal/mol). In conclusion, the results from this study suggest that the three synthetic curcumin derivatives have similar molecular interactions to curcumin with selected biological targets. However, in vitro and in vivo experimental studies are recommended to validate these findings.en_US
dc.description.departmentObstetrics and Gynaecologyen_US
dc.description.librarianam2024en_US
dc.description.sdgSDG-03:Good heatlh and well-beingen_US
dc.description.sponsorshipThe South African Medical Research Council (SAMRC) biomedical and research innovation platform (BRIP) and the NRF Thuthuka Programme.en_US
dc.description.urihttps://www.mdpi.com/journal/ijmsen_US
dc.identifier.citationMoetlediwa, M.T.; Jack, B.U.; Mazibuko-Mbeje, S.E.; Pheiffer, C.; Titinchi, S.J.J.; Salifu, E.Y.; Ramharack, P. Evaluating the Therapeutic Potential of Curcumin and Synthetic Derivatives: A Computational Approach to Anti-Obesity Treatments. International Journal of Molecular Sciences 2024, 25, 2603. https://DOI.org/10.3390/ijms25052603.en_US
dc.identifier.issn1661-6596 (print)
dc.identifier.issn1422-0067 (online)
dc.identifier.other10.3390/ijms25052603
dc.identifier.urihttp://hdl.handle.net/2263/101453
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.rights© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.en_US
dc.subjectPharmacokineticsen_US
dc.subjectPharmacodynamicsen_US
dc.subjectObesityen_US
dc.subjectCurcuminen_US
dc.subjectSynthetic curcumin derivativesen_US
dc.subjectSDG-03: Good health and well-beingen_US
dc.titleEvaluating the therapeutic potential of curcumin and synthetic derivatives : a computational approach to anti-obesity treatmentsen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Moetlediwa_Evaluating_2024.pdf
Size:
23.47 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: